Abstract
Crosstalk between G protein-coupled receptors (GPCRs) is one of the key mechanisms used by the cell for integrating multiple signaling pathways. Functional crosstalk at the level of signaling pathways was initially thought to regulate receptor function. Importantly, the existence of GPCR heteromers demonstrates that direct physical interactions between GPCRs could also be behind the crosstalk phenomenon. Neurological disorders such as Parkinsons disease (PD) and schizophrenia have been linked to a dysfunctional communication between certain GPCRs. In this review, we discuss functional and physical crosstalk of the main GPCR families involved in the aforementioned disorders. In addition, we analyze the available structural information on physical crosstalk and highlight some strategies in drug discovery based on these crosstalk mechanisms.
Keywords: Dimerisation, drug discovery, GPCR, heteromers, receptor crosstalk, receptor signaling, Parkinson disease, schizophrenia, Neurological disorders, crosstalk mechanisms
Current Medicinal Chemistry
Title: Crosstalk within GPCR Heteromers in Schizophrenia and Parkinsons Disease: Physical or Just Functional?
Volume: 19 Issue: 8
Author(s): R. Guixa-Gonzalez, A. Bruno, M. Marti-Solano and J. Selent
Affiliation:
Keywords: Dimerisation, drug discovery, GPCR, heteromers, receptor crosstalk, receptor signaling, Parkinson disease, schizophrenia, Neurological disorders, crosstalk mechanisms
Abstract: Crosstalk between G protein-coupled receptors (GPCRs) is one of the key mechanisms used by the cell for integrating multiple signaling pathways. Functional crosstalk at the level of signaling pathways was initially thought to regulate receptor function. Importantly, the existence of GPCR heteromers demonstrates that direct physical interactions between GPCRs could also be behind the crosstalk phenomenon. Neurological disorders such as Parkinsons disease (PD) and schizophrenia have been linked to a dysfunctional communication between certain GPCRs. In this review, we discuss functional and physical crosstalk of the main GPCR families involved in the aforementioned disorders. In addition, we analyze the available structural information on physical crosstalk and highlight some strategies in drug discovery based on these crosstalk mechanisms.
Export Options
About this article
Cite this article as:
Guixa-Gonzalez R., Bruno A., Marti-Solano M. and Selent J., Crosstalk within GPCR Heteromers in Schizophrenia and Parkinsons Disease: Physical or Just Functional?, Current Medicinal Chemistry 2012; 19 (8) . https://dx.doi.org/10.2174/092986712799320574
DOI https://dx.doi.org/10.2174/092986712799320574 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy in Liver Ischemia and Reperfusion Injury
Current Pharmaceutical Design Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Scopolamine and Depression: A Role for Muscarinic Antagonism?
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Positron Emission Tomography (PET) in Medicinal Chemistry and Drug Discovery (Guest Editor: Ming-Rong Zhang)]
Current Topics in Medicinal Chemistry Social Networks and Health in Women: Results from a Qualitative Study in Iran
Current Women`s Health Reviews Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats
Current Bioactive Compounds Obesity: An Emerging Importance of Progenitors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Search for γ-Secretase and Development of Inhibitors
Current Medicinal Chemistry A RasMol study of the Mechanism of Inhibition of Cysteine Endopeptidase Enzyme Papain
Current Proteomics Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Sigma-1 Receptor Chaperones and Diseases
Central Nervous System Agents in Medicinal Chemistry Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine A Bibliometric Analysis of Recent Arab Countries Research Activities in Renewable Energy (1966-2014)
Recent Innovations in Chemical Engineering Hippocampal Neurogenesis, Neurotrophic Factors and Depression: Possible Therapeutic Targets?
CNS & Neurological Disorders - Drug Targets Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Current Alzheimer Research From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research Synthesis and Evaluation of Chalcone and its Derivatives as Potential Anticholinergic Agents
Letters in Drug Design & Discovery The MMP-2/TIMP-2 System in Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Nanoparticles and Immune Cells
Current Pharmaceutical Design